BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 4038578)

  • 1. Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections.
    Rodriguez JR; Ramirez-Ronda CH
    Am J Med; 1985 Feb; 78(2A):42-3. PubMed ID: 4038578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.
    Rodríguez JR; Ramírez-Ronda CH; Nevárez M
    Antimicrob Agents Chemother; 1985 Feb; 27(2):246-51. PubMed ID: 4039118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections.
    Swabb EA; Cone CO; Muir JG
    Rev Infect Dis; 1985; 7 Suppl 4():S675-8. PubMed ID: 3909323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia.
    Schentag JJ; Vari AJ; Winslade NE; Swanson DJ; Smith IL; Simons GW; Vigano A
    Am J Med; 1985 Feb; 78(2A):34-41. PubMed ID: 3881947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli.
    Nolen TM; Phillips HL; Hall HJ
    Rev Infect Dis; 1985; 7 Suppl 4():S666-8. PubMed ID: 3909321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections.
    Rivera-Vazquez CR; Ramirez-Ronda CH; Rodriguez JR; Saavedra S
    Chemotherapy; 1989; 35 Suppl 1():89-100. PubMed ID: 2659296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the clinical effectiveness of aztreonam in gram-negative infections of the biliary tract].
    Pedretti G; Magnani G
    G Ital Chemioter; 1988; 35(1-3):45-8. PubMed ID: 3256512
    [No Abstract]   [Full Text] [Related]  

  • 8. The place of tobramycin in lower respiratory tract infections (LRTI).
    Gialdroni Grassi G
    J Chemother; 1995 Aug; 7(4):344-54. PubMed ID: 8568545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aztreonam plus clindamycin as therapy for pelvic infections in women.
    Pastorek JG; Cole C; Aldridge KE; Crapanzano JC
    Am J Med; 1985 Feb; 78(2A):47-50. PubMed ID: 4038579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative clinical efficacy and safety of netilmicin and tobramycin in children with serious gram-negative infections.
    Weippl G
    Clin Ther; 1983; 5(4):342-7. PubMed ID: 6347380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aztreonam therapy for gram-negative pneumonia.
    Greenberg RN; Reilly PM; Luppen KL; Bollinger M; McMillian R
    Am J Med; 1985 Feb; 78(2A):31-3. PubMed ID: 3918444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections.
    Chaudhary M; Shrivastava SM; Sehgal R
    Curr Clin Pharmacol; 2009 Jan; 4(1):62-6. PubMed ID: 19149503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra-abdominal infections.
    Birolini D; Moraes MF; de Souza OS
    Chemotherapy; 1989; 35 Suppl 1():49-57. PubMed ID: 2659290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam plus clindamycin vs. tobramycin plus clindamycin for the treatment of intraabdominal infections.
    Birolini D; Moraes MF; de Souza OS
    Rev Infect Dis; 1985; 7 Suppl 4():S724-8. PubMed ID: 3909330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of tobramycin in respiratory and systemic infections in immunodepressed and normal patients.
    Altucci P; Abbate GF; Alagia I; Leonessa V
    J Infect Dis; 1976 Aug; 134 Suppl():S182-6. PubMed ID: 972280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aztreonam treatment of severe infections caused by gram-negative aerobic bacilli].
    Peter JD; Jehl F; Froehly S; Dupeyron JP; Monteil H; Rosset MA
    Pathol Biol (Paris); 1988 May; 36(5):525-30. PubMed ID: 3043352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
    Henry SA; Bendush CB
    Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A; Steru D; Rosset MA; Carbon C
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tobramycin. Bacteriological studies and clinical activity in urinary and extra-urinary infections].
    Abbate GF; Alagia I; Gattoni A; Leonessa V; Manguso L; Altucci P
    G Ital Chemioter; 1977; 24(1-2):33-7. PubMed ID: 615760
    [No Abstract]   [Full Text] [Related]  

  • 20. Overall clinical experience with aztreonam in the treatment of intraabdominal infections.
    Henry SA
    Rev Infect Dis; 1985; 7 Suppl 4():S729-33. PubMed ID: 3909331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.